A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

Trial Profile

A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2016

At a glance

  • Drugs Rasagiline (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms MODERATO
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 25 Apr 2015 Baseline data presented at the 67th Annual Meeting of the American Academy of Neurology.
    • 26 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 29 Oct 2014 Planned End Date changed from 1 Oct 2014 to 1 Feb 2015 as reported byClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top